Are you curious about the latest advancements in AI-enabled antibody discovery? In this podcast series, we dive into the world of Antiverse - we are accelerating drug discovery against difficult targets, including GPCRs and ion channels, using machine learning and phage display techniques.
Join us as we discuss our mission to target cancer, cardiovascular disease, and other challenging conditions. Discover how we leverage AI and wet lab innovation to accelerate the discovery and development of biologics. Plus, learn about our unique approach to antibody discovery, our progress with our internal pipeline of antibodies against GPCRs and other challenging targets, as well as our exciting ongoing collaborations. Tune in and join us at the forefront of antibody discovery!
Things mentioned:
Additional Materials:
About Antiverse:
Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.
In this captivating podcast series, we dive deep into the world of computational antibody discovery with Ben Holland, our Co-Founder and CTO at Antiverse. Join us as we uncover the immense potential of merging computational and experimental techniques in the pursuit of revolutionary antibodies, as Ben sheds light on the strong benefits and formidable challenges encountered when targeting complex molecules such as GPCRs. With an emphasis on precision and accuracy in predicting antibody-antigen interactions, Ben shares remarkable insights and breakthroughs achieved by computational discovery techniques. Tune in and join us at the forefront of antibody discovery!
Things mentioned:
Additional Materials:
About Antiverse:
Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.
In this talk, Murat speaks with Tzvika Hartman, Senior Vice President of Computation at Biolojic Design, a company curating AI-designed antibodies focused on autoimmune diseases and immuno-oncology applications.
Biolojic uses machine learning to design 'programmable' antibodies with more precise molecular effects. These antibodies work dynamically with their environment, both temporally and spatially, opening avenues for new ways to alter biology. Their lead candidate, AU-007, pioneered by spin-out company Aulos Bioscience, is being advanced through Phase II clinical studies in solid tumour cancers.
Don't miss this exciting opportunity to learn about the technology and strategies at Biolojic Design directly from Tzvika. Furthermore, we'll be exploring Tzvika's fascinating and eventful career.
About Tzvika:
Tzvika has more than 30 years of experience in computer science research and software engineering. He worked at Google, Tel Aviv for 8 years as a software engineer, before founding Google's Health group in Tel Aviv, leading various projects over 5 years. Tzvika now leads the computational advancements at Biolojic Design.
Things mentioned:
Additional Materials:
About Antiverse:
Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.
Never miss a future event!
We'll notify you when there's a new event scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
LinkedIn: https://www.linkedin.com/company/antiverse/
Twitter (x.com) : https://twitter.com/AntiverseHQ
In this talk, Murat speaks with Abhishek Pandey, Principle Research Scientist and Pharma Discovery Group Lead at AbbVie.
Abhishek currently leads RAIDERS, a Pharma Discovery group integrating machine learning across all of AbbVie's working groups to augment drug discovery capabilities. Abhishek's groups work spans cheminformatics, imaging research, multi-omics, as well as the computation behind many of AbbVie's current partnerships and collaborations.
We'll be exploring how the machine learning group is transforming the processes across multiple working groups at the pharmaceutical giant, AbbVie. We'll also be unravelling the story of how Abhishek began his pioneering work at AbbVie.
You will learn:
About Abhishek:
Abhishek started his career as a software engineer at Toshiba. Following this, Abhishek began his PhD in medical engineering and image processing at the University of Arizona. This led Abhishek to become a core member of the precision medicine AI team at Tempus, developing ways to improve cancer imaging pipelines to help oncologists detect cancers more efficiently. Abhishek then joined AbbVie, where he founded the machine learning / deep learning team - the influence of which has expanded across the entire company.
Things mentioned:
Additional Materials:
First time hearing about Antiverse?
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
Never miss a future event!
We'll notify you when there's a new event scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
LinkedIn: https://www.linkedin.com/company/antiverse/
Twitter (x.com) : https://twitter.com/AntiverseHQ
This episode is a discussion between Rahmad Akbar, Senior Data Scientist in Antibody Design at Novo Nordisk and Murat Tunaboylu, Co-Founder and CEO of Antiverse.
You will learn:
Rahmad's LinkedIn page.
Rahmad's Personal Website.
Antibody Origami: Here.
Rahmad's Previous and Existing Team: Victor Greiff (GreiffLab). Paolo Marcatili, Ludovica Beltrame, Rasmus Høiberg-Nielsen (Antibody Design at Novo Nordisk).
"And a big shout out to budding antibody designers (scientists) everywhere especially from my home country Indonesia!' - Rahmad.
Be sure to like, rate and review the podcast if you enjoyed this episode! Visit our website: https://www.antiverse.io/ Follow us: LinkedIn: https://www.linkedin.com/company/antiverse/ X: https://twitter.com/AntiverseHQ
This episode is a discussion between Paul Essery, Host of 'The Tech Business Podcast' and Murat Tunaboylu Co-Founder and CEO of Antiverse.
You will learn:
Be sure to like, rate and/or review the podcast if you enjoyed it!
Visit our website: https://www.antiverse.io/
Follow us:
LinkedIn: https://www.linkedin.com/company/antiverse/
In this episode, we speak with Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.
Host: Murat Tunaboylu, Co-Founder and CEO of Antiverse.
You will learn:
Things mentioned:
Additional Materials:
First time hearing about Antiverse?
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
Never miss a future event!
We'll notify you when a new event is scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
LinkedIn: https://www.linkedin.com/company/antiverse/
In this episode, we speak with Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery at MilliporeSigma, the Global Science and Technology Group at Merck.
Host: Murat Tunaboylu, Co-Founder and CEO of Antiverse.
You will learn:
Things mentioned:
Additional Materials:
First time hearing about Antiverse?
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
Never miss a future event!
We'll notify you when a new event is scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
LinkedIn: https://www.linkedin.com/company/antiverse/
In this talk, Murat speaks with Ming (Tommy) Tang, Director of Computational Biology at Immunitas Therapeutics, an immuno-oncology start-up developing novel therapeutics for patients with cancer.
Tommy is a strong leader and communicator in the field of computational biology. He has dedicated his life's work to accelerating cancer research, with prominent expertise in analysing large-scale bulk sequencing data, single-cell and spatial transcriptomic data and epigenetic data.
Outside of his career at Immunitas, Tommy is a brilliant science communicator and teacher, with various educational streams, including Twitter, a blog, a GitHub repository, a YouTube channel, a newsletter, as well as authoring his own book, 'From Cell Line To Command Line'. He is passionate about teaching biologists the computational skills essential for modern science.
You will learn:
Things mentioned:
Link to all Tommy's resources: https://tommytang.bio.link/
Additional Materials:
First time hearing about Antiverse?
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
Never miss a future event!
We'll notify you when there's a new event scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
In this talk, Murat speaks with Nikhil Podduturi, Head of Data Science at the Digital Lab of Boehringer Ingelheim - (BI X).
Nikhil co-leads the laboratory and data science chapters at the BI X headquarters in Germany and China. The team at BI X is pioneering digital innovations to improve the lives of patients and animals. The current technologies developed by BI X include PetPro Connect, Farmera, and Pathological Speech Processing, with impacts spanning multiple healthcare fields.
Nikhil's current work involves developing new tools to accelerate drug discovery with advanced genetic sequencing technologies, designing new in silico systems to identify indications for drugs, as well as incorporating AI and ML technologies across BI X's digital health platforms.
You will learn:
Things mentioned:
Additional Materials:
First time hearing about Antiverse?
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
Never miss a future event!
We'll notify you when there's a new event scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
In this episode, we speak with Alan Nafiiev, Co-Founder and CEO of ‘RECEPTOR.AI’, an Artificial Intelligence (AI)-drug discovery company focused on screening small drug molecule candidates against difficult-to-drug targets.
Alan gives some key insights into the history of Receptor AI, the company's successes and obstacles, and how Receptor AIs 'software as a service' (SaaS) and services are streamlining the drug discovery process for pharmaceutical and biotech companies. He also discusses how Receptor AIs technology can automate and customise drug discovery pipelines.
To conclude, Alan explains Receptor AIs plans for 2023 - branching into membranotropic drug discovery for cancer and cardiovascular diseases, through designing drugs against unique membrane environments.
Things mentioned:
Additional Materials:
Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.
Arctoris COO Tom Fleming talks about automation and building a small molecule discovery platform
In this episode, our guest Assistant Prof. Tim Jenkins talks about snakebites and how to use AI to design broadly neutralising antibodies against venoms. Tim takes us through his experience at Milner Therapeutics Institute and shares his passion and vision for connecting academia and startups/industry players. In the second half of this talk, Tim explains the complexity in the venom domain and the challenges that lie ahead for the commercialisation of antivenom antibodies.
PS: Recently, with InstaDeep, Tim has posed a snake antivenom challenge as part of the largest hackathon in Africa.
In episode 4, Murat talks with Andrew C. R. Martin, Professor of Bioinformatics and Computational Biology at UCL, about abYsis (a fully integrated antibody discovery system) and the latest antibody developability tools!
Following the origin story of abYsis, you will hear the differences between the public and commercial versions such as data persistence and security, as well as new tools such as abYmod and abYdraw.
At the end of the talk, the discussion moves into developability (stability and Immunogenicity).
Antiverse - Engineering the future of drug discovery - https://www.antiverse.io/
To obtain an abYsis license contact Chemogenomix.
To be an abYdraw beta tester contact Andrew Martin.
Future of Drug Discovery Episode #3
In this session, Murat talks with Konrad Krawczyk, Assistant Professor SDU and Founder of NaturalAntibody.
We will be covering Mr Natural Antibody's views on developing and using bioinformatics tools to analyse and discover biologics.
Other topics in this episode:
- Changing role of bioinformatics from assisting to being the main driver in biologics discovery
- 99% of the job is to get quality data, 1% is computational methods
- Collecting data from Patents, Scientific Publications, NGS, Therapeutics from FDA
- Developing models for binding prediction and biophysical properties
- Predictions of binding and developability, database, tool access, and expertise
- Interpretability of ML models
Antiverse - Engineering the future of drug discovery - https://www.antiverse.io/
In this episode, Murat talks with Ryan Kelly about Abveris (employee #3) and how to run 100+ discovery campaigns against challenging targets.
FODD 1 - Victor Greiff - Immunology and Machine Learning Applied to Drug Discovery
